Tocilizumab for refractory and/or relapsing polyarteritis nodosa - 10/12/25
Doi : 10.1016/j.jaad.2025.11.014
Adrien Cottu, MD a, ⁎ 
, Chloé Grolleau, MD, PhD a, b, Camille Gandon, MD c, Thibault Mahévas, MD a, Clémence Lepelletier, MD a, Florence Cordoliani, MD a, Anne Contis, MD d, Estibaliz Lazaro, MD, PhD e, Cédric Léonard, MD e, Raluca Sterpu, MD f, Patricia Senet, MD g, Achilla Aouba, MD, PhD h, Emmanuelle Weber, MD i, Cécile Morice, MD j, Emma Huard, MD k, Adrien Sanchez, MD l, Nicolas Limal, MD m, Thibault Maillet, MD n, Benjamin Terrier, MD, PhD o, p, Maxime Battistella, MD, PhD i, Jean-David Bouaziz, MD, PhD a, b, Marie Jachiet, MD, PhD a, b
, Chloé Grolleau, MD, PhD a, b, Camille Gandon, MD c, Thibault Mahévas, MD a, Clémence Lepelletier, MD a, Florence Cordoliani, MD a, Anne Contis, MD d, Estibaliz Lazaro, MD, PhD e, Cédric Léonard, MD e, Raluca Sterpu, MD f, Patricia Senet, MD g, Achilla Aouba, MD, PhD h, Emmanuelle Weber, MD i, Cécile Morice, MD j, Emma Huard, MD k, Adrien Sanchez, MD l, Nicolas Limal, MD m, Thibault Maillet, MD n, Benjamin Terrier, MD, PhD o, p, Maxime Battistella, MD, PhD i, Jean-David Bouaziz, MD, PhD a, b, Marie Jachiet, MD, PhD a, b a Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
b Unité 976 HIPI, INSERM Human Immunology, Physiopathology and Immunotherapy, Hospital Saint-Louis, Paris, France
c Department of Pathology, AP-HP Saint-Louis Hospital, Université Paris Cité, INSERM U976 HIPI Team 1, Paris, France
d Department of Internal Medicine and Clinical Immunology, Saint Andre Hospital, University Hospital Centre of Bordeaux, Bordeaux, France
e Department of Internal Medicine and Infectious Diseases, Haut-Leveque Hospital, University Hospital Centre of Bordeaux, Pessac, France
f Department of Internal Medicine and Clinical Immunology, Hôpital Antoine-Béclère AP-HP, Clamart, France
g Dermatology and Vascular Medicine Department, Tenon University Hospital, Paris, France
h Department of Internal Medicine, Caen University Hospital, 14000 Caen, France
i Department of Internal Medicine, CHU Groupement Hospitalier Nord, Hopital de la Croix Rousse, Lyon, France
j Department of Dermatology, CHU Caen, Caen, France
k Department of Dermatology, CHU Nice, Nice, France
l Department of Medical Specialities, Dermatology, Princess Grace Hospital, Monaco, Principality of Monaco
m Department of Internal Medicine, CHU Henri Mondor, Créteil, France
n Department of Internal Medicine - Centre Hospitalier de Mâcon, Groupe Hospitalier Bourgogne Méridionale, Macon, France
o Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
p Université Paris Cité, Paris, France
∗Correspondence to: Adrien Cottu, MD, Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, 1 Ave Claude Vellefaux, Paris, 75010, FranceDermatologyDepartmentHôpital Saint-LouisAssistance Publique-Hôpitaux de Paris1 Ave Claude VellefauxParis75010France
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Wednesday 10 December 2025
Key words : biologic, cutaneous polyarteritis nodosa, tocilizumab, treatment, vasculitis
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: This study was approved by the local ethics committee (« Comité Local d’éthique pour les publications de l'hôpital Cochin (CLEP) »): decision N°: AAA-2024-10029. |
© 2025
The Author(s). Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?